Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Asan Medical Center
INSYS Therapeutics Inc
European Organisation for Research and Treatment of Cancer - EORTC